% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@MISC{Ceccon:908208,
      author       = {Ceccon, Garry and Lohmann, Philipp and Tscherpel, Caroline
                      and Dunkl, Veronika and Rapp, Marion and Stoffels, Gabriele
                      and Herrlinger, Ulrich and Rosen, Jurij and Wollring,
                      Michael and Shah, Nadim J and Fink, Gereon R and Langen,
                      Karl-Josef and Galldiks, Norbert},
      title        = {{NIMG}-79. {EARLY} {TREATMENT} {RESPONSE} {ASSESSMENT}
                      {USING} {O}-(2-18{F}-{FLUOROETHYL})-{L}-{TYROSINE} ({FET})
                      {PET} {COMPARED} {TO} {MRI} {IN} {MALIGNANT} {GLIOMAS}
                      {TREATED} {WITH} {ADJUVANT} {TEMOZOLOMIDE} {CHEMOTHERAPY}},
      issn         = {1523-5866},
      reportid     = {FZJ-2022-02459},
      year         = {2018},
      abstract     = {AbstractBACKGROUNDThe goal of this prospective study was to
                      compare the value of conventional MRI and
                      O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET for response
                      assessment in patients with malignant glioma treated with
                      first-line adjuvant temozolomide chemotherapy
                      (TMZ).METHODSAfter biopsy/resection and completion of
                      radiotherapy with concomitant temozolomide, 34 malignant
                      glioma patients (glioblastoma, n=31; IDH-wildtype anaplastic
                      astrocytoma, n=2; H3K27-mutated midline glioma, n=1) (age
                      range, 20–66 years) were subsequently treated with
                      adjuvant TMZ (5/28). FET-PET scans were performed at
                      baseline and after 10–12 weeks. The first follow-up MRI
                      after radiotherapy (9 ± 3 weeks) was compared with the
                      early postoperative MRI. We obtained FET metabolic tumor
                      volumes (MTV) and tumor/brain ratios (TBR). Threshold values
                      of FET-PET parameters for treatment response were
                      established by ROC analyses using the progression-free
                      survival (PFS) ≤/>9 months as reference. MRI response
                      assessment was based on RANO criteria. The predictive
                      ability of FET-PET thresholds and MRI changes on early
                      response assessment was evaluated subsequently concerning
                      PFS using univariate survival estimates.RESULTSRelative TBR
                      changes were not predictive for a PFS>9 months (P>0.05),
                      whereas the absolute MTV at follow-up significantly
                      predicted a PFS>9 months (P=0.016; threshold, 14.5 ml). The
                      relative MTV change enabled the most significant PFS
                      prediction. Responders defined by relative MTV changes
                      (threshold, $≤0\%)$ had a significantly 2-fold longer PFS
                      than non-responders (16 vs. 8 months, P=0.003). RANO
                      criteria at the first follow-up MRI after radiotherapy were
                      not predictive for a PFS>9 months (P=0.260). CONCLUSIONS:
                      FET-PET appears to be useful for identifying responders to
                      adjuvant TMZ early after treatment initiation.},
      cin          = {INM-4 / INM-11 / JARA-BRAIN},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-4-20090406 / I:(DE-Juel1)INM-11-20170113 /
                      I:(DE-Juel1)VDB1046},
      pnm          = {5253 - Neuroimaging (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253},
      typ          = {PUB:(DE-HGF)4},
      doi          = {10.1093/neuonc/noy148.801},
      url          = {https://juser.fz-juelich.de/record/908208},
}